Northwest & Ethical Investments L.P. Trims Holdings in Insmed Incorporated (NASDAQ:INSM)

Northwest & Ethical Investments L.P. lowered its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 34.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,050 shares of the biopharmaceutical company’s stock after selling 550 shares during the period. Northwest & Ethical Investments L.P.’s holdings in Insmed were worth $77,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. V Square Quantitative Management LLC acquired a new stake in shares of Insmed during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC grew its position in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares during the period. First Horizon Advisors Inc. increased its stake in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares during the period. Finally, CWM LLC lifted its stake in shares of Insmed by 11.0% in the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 155 shares during the last quarter.

Insmed Stock Down 0.9 %

INSM stock opened at $75.16 on Monday. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The company’s 50 day moving average price is $72.20 and its 200 day moving average price is $68.34. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $13.45 billion, a price-to-earnings ratio of -13.54 and a beta of 1.12.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The company’s revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.10) earnings per share. On average, equities research analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the sale, the insider now owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. This trade represents a 29.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. The trade was a 11.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,882 shares of company stock valued at $5,765,446. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

INSM has been the topic of several research analyst reports. Stifel Nicolaus boosted their price objective on shares of Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a report on Friday, August 9th. TD Cowen upped their price objective on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Bank of America boosted their target price on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.